Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
O60260
UPID:
PRKN_HUMAN
Alternative names:
Parkin RBR E3 ubiquitin-protein ligase; Parkinson juvenile disease protein 2
Alternative UPACC:
O60260; A3FG77; A8K975; D3JZW7; D3K2X0; Q5TFV8; Q5VVX4; Q6Q2I6; Q8NI41; Q8NI43; Q8NI44; Q8WW07
Background:
E3 ubiquitin-protein ligase parkin, also known as Parkin RBR E3 ubiquitin-protein ligase and Parkinson juvenile disease protein 2, plays a pivotal role in protein degradation pathways. It functions within a multiprotein E3 ubiquitin ligase complex, catalyzing the covalent attachment of ubiquitin moieties onto substrate proteins. This process is crucial for the removal and detoxification of abnormally folded or damaged proteins, thereby maintaining cellular homeostasis.
Therapeutic significance:
Parkin is intricately linked to neurodegenerative disorders, notably Parkinson disease and Parkinson disease 2. Its involvement in the ubiquitination of specific substrates related to these diseases highlights its potential as a target for therapeutic intervention. Understanding the role of E3 ubiquitin-protein ligase parkin could open doors to potential therapeutic strategies, especially in mitigating the progression of Parkinson's disease and related neurodegenerative conditions.